• our science our science Our Science
    • By Industry

      • Bioprocessing

        • Upstream

        • Downstream

        • Fill/Finish

        • Oligonucleotides

      • Cell and Gene Therapy

        • Upstream

        • Downstream

        • Fill/Finish

        • Oligonucleotides

      • Pharmaceutical

        • Oligonucleotides

        • Small Molecule

    • By Application

      • Buffer Prep

        • Chemical and Bioprocessing Containers

        • Filtration and Purification

      • Bulk Fill

      • Cell Growth

      • Cell Separation

        • Filtration and Purification

      • Facilities/Bulk Chemicals

        • Chemical and Bioprocessing Containers

      • Fill/Finish

      • Freezing

      • Media Prep

        • Filtration and Purification

      • Medical Devices

        • Dental

        • Eye Care

        • Implantable Devices

        • Medical Ultrasound

        • Wound Care

      • Quality Control

      • RNA and DNA Solutions

        • Oligonucleotides

      • Small Molecule

        • Liquid Filters

        • Catalysts

        • Ligands

        • Organophosphorus Compounds

        • Filtration and Purification

      • Storage

        • Chemical and Bioprocessing Containers

    • By Location

      • Hangzhou Facility

      • Life Sciences Technology Center

  • product catalog product catalog Product Catalog
    • Single-Use Assemblies

      • 2D and 3D Bags

      • Mixing Systems

      • Motion Bioreactor Bags

      • Microcarrier and Cell Separation Systems

      • Tube Sets and Manifolds

    • Filtration and Purification

      • Liquid Filters

      • Vent Gas Filters

    • Fluid Management

      • Tube Sets and Manifolds

      • Cynergy® Valves

      • Cynergy® Fittings

      • Custom Dip Tubes, Tanks, and Containers

      • Tubing and Pipe

    • Process Monitoring

      • Particle Characterization

    • Chemical Packaging

      • FluoroPure® HDPE Blowmolded Drums

        • FluoroPure® Trilayer HDPE Blowmolded Drums

        • FluoroPure® Advantage Trilayer HDPE Blowmolded Drums

      • NOWPak® Liner-Based Systems

      • FluoroPure® Composite Drums

      • FluoroPure® Intermediate Bulk Containers

      • Sentry® Quick Connect Systems

      • Rigid Bioprocessing Support Containers

    • Specialty Chemicals

      • Catalysts

      • Ligands

      • Organophosphorus Compounds

      • Siloxanes

      • Specialty Acrylates and Methacrylates

      • Specialty Additives

    • Premium Graphite

      • Life Sciences Graphite Grades

      • Premium Graphite Components

      • Graphite Processing Options

    • Liquid Filters

  • resources resources Resources
    • Industry Insights

      • Aramus™ Shaped 2D Single-Use Bags

      • Cell and Gene Therapy

      • Cold Chain Bioprocessing

      • Filter Bag Assembly

      • High-Density Cell Banking

      • Life Sciences Filtration

      • Low-Temperature Bioprocessing

      • Nanoparticles

      • Pandemic Response

      • Particle Characterization

      • Single-Use Solutions for Bioprocessing

      • USP Subvisible Particulate Testing

    • Reference Materials

    • Technical Information

      • Chemical Compatibility

      • Material Properties and Safety

      • Particle Characterization Applications

    • Entegris Blog

  • about us about us About Us
    • Corporate Overview

    • Corporate Social Responsibility

    • Careers

    • Events

    • Investor Relations

    • Legal/Trademark Notices

    • Locations

    • News Releases

    • Media Coverage

    • Entegris Blog

Entegris Expands Life Sciences Production Capacity and Capabilities

The expansion of production facilities and development of a dedicated Life Sciences Technology Center address the increased demand for bioprocessing assemblies.

News Release
Download PDF (180.0 kB)

Billerica, MA – Entegris, Inc. (NASDAQ: ENTG), a world-class supplier of advanced materials and process solutions for the semiconductor and other high-technology industries, today announced the expansion of its Life Sciences manufacturing facilities located in Billerica, MA; Bloomington, MN; and Logan, UT. 

The expansions are part of Entegris’ capital expenditures plan to invest approximately $30 million in life sciences capacity and capabilities this year, in addition to the $10 million invested in 2020. The facilities will develop and manufacture bioprocessing assemblies, such as its Aramus™ critical fluid handling product line currently used to produce and deliver vaccines worldwide. The company anticipates hiring nearly 200 additional employees with engineering and production experience throughout 2021 to support increased demand for its products. 

Entegris also has started development of its Life Sciences Technology Center located at its headquarters in Billerica, MA. The facility will be dedicated to providing application testing, process development, and solution demonstration services for bioprocess technologies including freeze, thaw, and filtration applications.

Bertrand Loy, Entegris’ president and chief executive officer, said the company recognized that it was a natural partner to the life sciences industry due to its expertise in complex manufacturing processes with their rigorous requirements for achieving high purity and high yields. Although Entegris began developing solutions specific to bioprocessing needs before the COVID-19 pandemic, the company has more recently used its significant capabilities in advanced manufacturing environments to rapidly mobilize and provide key support to biopharmaceutical companies in the race to safely develop, produce and distribute a vaccine.

“With more than 50 years of experience serving industries with complex specifications, we understand the importance of process stability, consistency, safety and speed in bioprocessing. Entegris’ life sciences solutions have proven to be invaluable to biopharmaceutical companies in successfully delivering COVID-19 vaccines to the global population. Our investment in expanding and developing facilities dedicated to life sciences capabilities further demonstrates the company's commitment to effectively serving this industry – now and in the future.”

The expansion of Entegris’ bioprocessing facilities comes as the pharmaceutical sector increases demand for  high-purity systems designed for freezing, transporting, storing, and thawing drug substances. In addition to COVID-19 vaccines, these solutions are also applicable in the production of other treatments and therapeutics. 

John Lynch, vice president of Life Sciences at Entegris, said, “Our capabilities and expertise have translated exceptionally well to the life sciences industry. We are proud to be partnering with biopharmaceutical companies to fight the COVID-19 pandemic by providing the cleanest and most robust bioprocessing assembly solutions on the market. The success of the Aramus™ bioprocessing assembly, due to its distinctive features for handling frozen bulk drug substances, has paved the way to better support novel biologic therapies of the future.” 

In addition to the Aramus 2D bag product line, Entegris provides other clean, scalable, and reliable bioprocessing solutions capable of reducing validation time, development costs, and time-to-market. Products include specialty and fine chemicals, fluid management technologies, particle characterization, liquid packaging, process analytics, filtration, and purification.

To learn about how Entegris is supporting the life sciences sector, visit www.entegris.com/life-sciences.

About Entegris
Entegris is a world-class supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. Entegris has approximately 5,800 employees throughout its global operations and is ISO 9001 certified. It has manufacturing, customer service, and/or research facilities in the United States, Canada, China, France, Germany, Israel, Japan, Malaysia, Singapore, South Korea, and Taiwan. Additional information may be found at www.entegris.com

Forward-Looking Statements
This news release contains forward-looking statements. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “forecast,” “project,” “should,” “may,” “will,” “would” or the negative thereof and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include statements related to future investments in capabilities and capacity; demand expectations for Entegris’ products; expected staffing levels; and other matters. These statements involve risks and uncertainties, and actual results may differ materially from those projected in the forward-looking statements.  These risks and uncertainties include, but are not limited to, those risk factors and additional information described in Entegris’ filings with the Securities and Exchange Commission, including under the heading “Risk Factors” in Item 1A of Entegris’ Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed with the Securities and Exchange Commission on February 5, 2021, and in Entegris’ other periodic filings. 

Media Contact:
Connie Chandler
Director of Corporate Communications
T +1 978-436-6546

Investor Contact:
Bill Seymour
VP of Investor Relations
T +1 952-556-1844